Overview

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

Status:
Completed

Trial end date:
2016-09-03

Target enrollment:

Participant gender:

Summary

The study was designed to evaluate the efficacy and safety of fingolimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Mitsubishi Tanabe Pharma Corporation

Treatments:

Fingolimod Hydrochloride